Regulating angiogenesis: A new therapeutic strategy

Journal of Clinical Pharmacology

Volumn 38, Issue 10, 1998, Pages 898-903

  Gibaldi, Milo ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; ALPHA2A INTERFERON; AMINOPEPTIDASE; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; COLLAGEN; CYCLOPHOSPHAMIDE; DNA; FIBROBLAST GROWTH FACTOR RECEPTOR; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GAMMA INTERFERON; GROWTH FACTOR; INTERFERON; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MELPHALAN; MEMBRANE PROTEIN; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LM 609; NEUTRALIZING ANTIBODY; PLASMINOGEN; RETINOID; THALIDOMIDE; THROMBOCYTE FACTOR 4; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; EXTRACELLULAR MATRIX; HEMANGIOMA; HUMAN; INTRACORONARY INFUSION; ISCHEMIC HEART DISEASE; KAPOSI SARCOMA; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; TERATOGENICITY; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; UTERINE CERVIX CANCER;

EID: 0031728332     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04384.x     Document Type: Review

References (23)

1. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
2. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 1995:333:1757-1763.
3. Gasl G, Hermann T, Steurer M, Zmija J, Gusilius E, Unger C, Kraft A: Angiogenesis as a target for tumor treatment. Oncology 1997;54:177-184.
4. Ezekowitz RAB, Mulliken JB, Folkman J: Interferon alpha-2a for life threatening hemangiomas of infancy. N Engl J Med 1992; 326:1456-1463.
5. Kudelka AP, Verschraegen CF, Lover E: Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. N Engl J Med 1998;338:991-992.
6. Denis LJ, Verweij J: Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest New Drugs 1997;15:175-185.
7. Evans JD, Ghaneh P, Dawesha A, Neoptolemos JP: Role of matrix metalloproteinases and their inhibitors in pancreatic cancer. Digestion 1997;58:520-528.
8. Cheresh DA: Death to blood vessel, death to a tumor. Nat Med 1998;4:395-396.
9. Pasqualini R, Koivunen E, Ruoslahti E: Alpha v integrins as receptors for tumor targeting by circulating ligands. Nature Biotechnol 1997;15:542-546.
10. Lienard D, Eggermont AM, Schraffordt-Koops H, Kroon BB, Rosenkaimer F, Autier P, Lejeune FJ: Isolated perfusion of the limb with high-dose tumor necrosis factor-alpha, interferon gamma, and melphalan for melanoma stage III: results of a multi-centre pilot study. Melanoma Res 1994:4(Suppl 1):21-26.
11. 3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nature Med 1998;4:408-414.
12. Gradishar WJ: An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action. Invest New Drugs 1997;15:49-59
13. Baringa M: Designing therapies that target tumor blood vessels. Science 1997;275:482-484.
14. O'Reilly MS, Holmgren L, Chen C, Folkman J: Angiostatin induces and sustains tumor dormancy of human primary tumors in mice. Nature Med 1996;2:6689-6692.
15. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
16. Boehm T, Folkman J, Browder T, O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:202-407.
17. Hanahan D: A flanking attack on cancer. Nature Med 1998;4: 13-14.
18. Ware JA, Simons M: Angiogenesis in ischemic heart disease. Nature Med 1997;3:158-163.
19. Yanagisawa-Miwa A, Uchida Y, Nakamura F, Tomura T, Kido H, Kamijo T, et al: Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 1992;257:1401-1403.
20. Schumacher B, Pecher P, von Sprecht BU, Stegmann T: Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary artery disease. Circulation 1998;97:645-650.
21. Folkman J: Angiogenic therapy of the human heart. Circulation 1998;97:628-629.
22. Arras M, Mollnau H, Strasser R, Wenz R, Ito WD, Schaper J, Schaper W: The delivery of angiogenic factors to the heart by microsphere therapy. Nature Biotechnol 1998;15:159-162.
23. 165 in patients with ischaemic limb. Lancet 1996;348: 370-374.